Francisco LePort is co-founder and CEO of Gordian Biotechnology. Gordian Biotechnology has developed in vivo perturb seq technology that simultaneously measures the safety and efficacy of thousands of arbitrary genetic perturbations, directly in individual living animal models of any given age-related disease. Having raised $60M to date, Gordian is developing first-in-class therapeutics for obesity, heart failure, kidney disease, and osteoarthritis. Prior to Gordian, Francisco graduated with a BS in Physics from UC Irvine at the age of 17, and a Ph.D. in Physics from Stanford University. He has over 15 years of experience applying AI to various industries as a founder, investor, board member, and employee of numerous Bay Area companies.